Access cutting-edge her2+ solid tumors treatment through this clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.
Access her2+ solid tumors specialists in Anchorage at no cost
This study follows strict safety protocols and ethical guidelines
All study-related her2+ solid tumors treatment provided free
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-expres
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this her2+ solid tumors clinical trial in Anchorage, AK
If you're searching for her2+ solid tumors treatment options in Anchorage, AK, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Anchorage research site is actively enrolling participants for this clinical trial. You'll receive care from experienced her2+ solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.